Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Working Capital Changes (2020 - 2025)

Historic Other Working Capital Changes for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $2.4 million.

  • Apellis Pharmaceuticals' Other Working Capital Changes rose 14784.27% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 12100.09%. This contributed to the annual value of -$20.4 million for FY2024, which is 4336.87% down from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Other Working Capital Changes is $2.4 million, which was up 14784.27% from -$8.0 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Other Working Capital Changes ranged from a high of $47.6 million in Q4 2021 and a low of -$44.5 million during Q2 2022
  • For the 5-year period, Apellis Pharmaceuticals' Other Working Capital Changes averaged around -$711263.2, with its median value being -$2.3 million (2023).
  • In the last 5 years, Apellis Pharmaceuticals' Other Working Capital Changes tumbled by 279268.44% in 2022 and then soared by 64229.58% in 2023.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Other Working Capital Changes stood at $47.6 million in 2021, then crashed by 73.7% to $12.5 million in 2022, then crashed by 275.1% to -$21.9 million in 2023, then surged by 75.38% to -$5.4 million in 2024, then soared by 144.16% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, -$8.0 million for Q2 2025, and $18.7 million during Q1 2025.